Download Files:
Products Details
Product Description
– CDK9-IN-22 is a potent CDK9 inhibitor with IC50s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity[1].
Web ID
– HY-151984
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H28FN5O2
References
– [1]Xu Z, et al. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors. Eur J Med Chem. 2022 Dec 15;244:114875.
CAS Number
– 2872677-61-5
Molecular Weight
– 485.55
SMILES
– CN(CCNC(C1=CC=C(C=C1)NC2=NC(C3=C(C=C(C=C3)F)OCC4=CC=CC=C4)=CC=N2)=O)C
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– CDK
Isoform
– CDK2;CDK9
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
